Clinical applications of hormonal therapy in ovarian cancer.
The ovary is an endocrine organ and an end organ. Hormones and their receptors have been associated with ovarian cancer and may be related to its causation. Some data suggest that hormonal therapies may have some effect on ovarian cancer in palliative settings. No hormonal therapy is approved by the US Food and Drug Administration (FDA) for the treatment of any type of ovarian malignancy nor is it listed as an active agent by any of the authoritative compendia. Because of the endocrine associations with ovarian cancer, the minimal side effects, and demonstrated activity of hormonal therapies in other endocrine-associated malignancies, further study is needed.
Rao
Gautam G
GG
University of Texas Southwestern Medical Center, Department of Obstetrics and Gynecology, 5323 Harry Hines Blvd., Dallas, TX 75390, USA.
Miller
David S
DS
D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects / Q000627:therapeutic use; D008525:Medroxyprogesterone / Q000009:adverse effects / Q000627:therapeutic use; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009367:Neoplasm Staging; D009570:Nitriles / Q000009:adverse effects / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D016729:Leuprolide; D008525:Medroxyprogesterone
Gynecol Oncol. 2002 Sep;86(3):297-301
12217751
J Reprod Med. 1996 Jun;41(6):393-6
8799913
Fertil Steril. 1993 Oct;60(4):672-4
8405523
Gynecol Oncol. 2004 Jul;94(1):25-32
15262115
Gynecol Oncol. 1986 Jul;24(3):299-308
2424810
JAMA. 2003 Oct 1;290(13):1739-48
14519708
Anticancer Drugs. 2001 Oct;12(9):719-24
11593052
Gynecol Oncol. 2003 Dec;91(3):596-602
14675683
Am J Clin Pathol. 2002 May;117(5):745-50
12090423
Semin Oncol. 1986 Dec;13(4 Suppl 4):26-32
3099393
J Nucl Med. 1972 Jan;13(1):101-6
4332571
J Clin Epidemiol. 1990;43(6):559-68
2348208
Gynecol Oncol. 1996 Jul;62(1):4-6
8690289
J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64
14652237
Am J Clin Oncol. 1998 Dec;21(6):565-7
9856656
Acta Oncol. 1995;34(6):813-20
7576750
J Natl Cancer Inst. 2002 Jan 2;94(1):32-8
11773280
Am J Clin Oncol. 1993 Apr;16(2):149-51
8452108
Eur J Cancer. 1994;30A(5):697-8
8080689
Obstet Gynecol. 1989 Dec;74(6):921-6
2685680
Clin Cancer Res. 2002 Jul;8(7):2233-9
12114425
Clin Obstet Gynecol. 2001 Mar;44(1):73-91
11219248
Br J Cancer. 1986 Mar;53(3):321-9
3083857
Cancer Res. 1984 Jun;44(6):2265-71
6722767
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD001034
20238312
Eur J Cancer. 2000 Sep;36 Suppl 4:S59-61
11056321
Oncology. 2004;66(2):112-7
15138362
J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):255-63
14623519
Br J Cancer. 1991 Mar;63(3):410-1
1825918
Bull Cancer. 1995 Jan;82(1):51-6
7742616
Am J Obstet Gynecol. 1985 Dec 15;153(8):877-82
3000183
J Natl Cancer Inst. 1983 May;70(5):839-45
6405069
Breast. 2004 Oct;13(5):363-8
15454190
Am J Clin Oncol. 1992 Apr;15(2):125-8
1553899
Hum Pathol. 1981 Oct;12(10):886-90
6271662
N Engl J Med. 1978 Dec 7;299(23):1261-6
101843
Int J Gynecol Cancer. 1995 Jul;5(4):301-305
11578494
Cancer. 1991 Jul 15;68(2):269-71
2070324
Gynecol Oncol. 2004 May;93(2):390-3
15099951
Gynecol Oncol. 2002 Feb;84(2):201-9
11812075
Ann Oncol. 2002 Feb;13(2):251-7
11886002
Am J Obstet Gynecol. 1989 Oct;161(4):905-10
2552807